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Introduction: There are many problems with current state-of-the-art protocols for 
maintenance dosing of the oral anticoagulant agent warfarin used in clinical practice.  
The two key challenges include lack of personalized dose adjustment and the high cost of 
monitoring the efficacy of the therapy in the form of International Normalized Ratio 
(INR) measurements.  A new dosing algorithm based on the principles of Reinforcement 
Learning (RL), specifically Q-Learning with functional policy approximation, was 
created to personalize maintenance dosing of warfarin based on observed INR and to 
optimize the length of time between INR measurements.  This new method will help 
improve patient’s INR time in therapeutic range (TTR) as well as minimize cost 
associated with monitoring INR when compared to the current standard of care. 
Procedure: Using the principles of Reinforcement Learning, an algorithm to control 
warfarin dosing was created.  The algorithm uses 9 different controllers which 
correspond to 9 different levels of warfarin sensitivity.  The algorithm switches between 
controllers until it selects the controller that most closely resembles the individual 
patient’s response, and thus the optimal dose change (       and time between INR 
measurements (       are personalized for each patient, based on INR observed in the 
patient.  Three simulations were performed using data from 100 artificial patients, 
iv 
 
generated based on data from real patients, each.  The first simulation that was performed 
was an ideal case scenario (clean simulation where the coefficient of variance (CV) of 
noise added to the model output = 0) using only the warfarin RL algorithm to prove 
efficacy.  The second simulation was performed using the current standard of care and a 
CV = 25% to simulate intra-patient variability.  The third simulation was performed 
using the warfarin RL algorithm with a CV = 25%.  180 days were simulated for each 
patient in each simulation and the measurements that were used to benchmark the 
efficacy of the therapy were INR time in therapeutic range (TTR) and the number of INR 
measurements that were taken during simulation. 
Results: The first simulation yielded a mean TTR = 92.1% with a standard deviation of 
4.2%, and had a mean number of INR measurements = 7.94 measurements/patient. The 
second simulation yielded a mean TTR = 45.3% with a standard deviation of 16.4%, and 
had a mean number of INR measurements = 12.3 measurements/patient. The third 
simulation yielded a mean TTR = 51.8% with a standard deviation of 10.8%, and had a 
mean number of INR measurements = 8.05 measurements/patient. A p-value <.001 
suggests that there is a statistically significant difference between the 2 algorithms. 
Conclusion: Results from the simulations indicate that the warfarin RL algorithm 
performed better than the standard of care at keeping the patient’s INR in therapeutic 
range and also reduced the number of INR measurements that were necessary.  This 
algorithm could help improve patient safety by increasing the patient’s INR TTR in the 
presence of intra-patient variability, and also help reduce the heavy cost associated with 
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A. Problem Statement 
There are a variety of different disease states and conditions where the use of 
prophylaxis is recommended to reduce the risk of thromboembolism in patients. These 
disease states and conditions include, but are not limited to, atrial fibrillation, heart valve 
replacements, deep vein thrombosis (DVT), and myocardial infarction (MI) (Merli & 
Tzanis, 2009). Common prophylaxes that are used in clinical practice include mechanical 
methods, such as compression sleeves, and pharmaceutical methods, such as 
anticoagulants. 
 Mechanical methods used to reduce the risk of thromboembolism include a 
variety of different types of compression sleeves.  Compression sleeves are used to apply 
pressure to areas of poor circulation, thereby reducing blood stasis (Larkin, Mitchell, & 
Petrie, 2012).  There are many different types of compression sleeves used in clinical 
practice including uniform compression sleeves, graduated compression sleeves, and 
intermittent pneumatic sleeves.  Uniform compression sleeves apply uniform pressure to 
the area that they are applied and are readily available to the entire population, whereas 
graduated compression sleeves vary the pressure they apply throughout the sleeve and are 
typically used in hospital settings (Larkin, Mitchell, & Petrie, 2012).  Intermittent 
pneumatic sleeves use pressure cuffs to repeatedly inflate and deflate around the area 
they are applied.  These sleeves can vary the amount of pressure they apply and can also 
be used to apply uniform or graduated pressure.  While compression sleeves have proven 
to be effective in reducing thromboembolism in conditions such as DVT and surgery 
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(Morris & Woodcock, 2004; MacLellan & Fletcher, 2007; Larkin, Mitchell, & Petrie, 
2012), there is no evidence to suggest that they could be effective in reducing 
thromboembolic events in conditions such as atrial fibrillation and MI. 
Pharmaceutical methods for reducing the risk of thromboembolic event are 
typically anticoagulant drugs including injectable drugs such as heparin and oral 
anticoagulant drugs such as dabigatran, rivaroxaban, and warfarin.  Heparin, specifically 
low molecular weight heparin, binds to antithrombin III which inactivates thrombin and 
factor Xa (Chuang, Swanson, Raja, & Olson, 2001).  Dabigatran is a direct thrombin 
inhibitor (Miller, Grandi, Shimony, Filion, & Eisenberg, 2012).  Rivaroxaban inhibits 
both free factor Xa and factor Xa (Miller, Grandi, Shimony, Filion, & Eisenberg, 2012).  
Warfarin is a vitamin K antagonist and works by inhibiting the synthesis of the Vitamin 
K dependent clotting factors II, VII, IX, and X (Porter, 2010).  While all of these drugs 
have proven to be effective in clinical practice, there are drawbacks associated with each.  
Injectable heparin can cause patient discomfort because of the need for injections, and 
even when it is taken orally, it still has a higher monetary cost when compared to other 
oral anti-coagulants (Looi, et al., 2013).  Due to the nature of these anticoagulant drugs, 
there is an increased risk of patient bleeding, and because of this, there is a need to take 
precautions while using anticoagulants for therapy.  Warfarin has an easy reversibility of 
action when compared to other oral anticoagulants, such as dabigatran and rivaroxaban, 
and due to this fact, it remains the most widely used oral anticoagulant in clinical practice 
today (The International Warfarin Pharmacogenetics Consortium, 2009).   
The standard for measuring the efficacy of warfarin therapy, first adopted in 1982 
by the World Health Organization, is known as the International Normalized Ratio (INR) 
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(Wardrop & Keeling, 2008).  Many of the indications for use of warfarin therapy specify 
a narrow therapeutic range of 2.0-3.0, and because of this there is a need for frequent INR 
measurements to minimize the risk of bleeding (when INR is too high), or 
thromboembolic event (when INR is too low) (Merli & Tzanis, 2009).  The high cost 
associated with warfarin therapy comes from the need for frequent INR measurements.  
These costs include not only the health care expenses (such as laboratory tests, 
equipment, labor, etc.), but also indirect costs such as time lost from work, travel 
expenses, and many others (Chambers, Chadda, & Plumb, 2009; Harrington, Armstrong, 
Nolan, & Malone, 2013; Lafata, Martin, Kaatz, & Ward, 2000). 
Because of the widely adopted use of warfarin oral anticoagulant therapy, there is 
a need for dosing algorithms to maintain the efficacy of the therapy while reducing the 
risk for bleeding or thromboembolic events.  The current standard of care for warfarin 
oral anticoagulant therapy, as dictated by the American Society of Hematology, is an 
expert-system type algorithm that provides no dosing personalization and also does not 
explicitly optimize the monitoring frequency of the efficacy of the therapy (Cushman, 
Lim, & Zakai, 2011).  While there are many other warfarin dosing algorithms that seek to 
improve the efficacy of warfarin therapy, including pharmacogenetic algorithms 
(Carlquist & Anderson, 2011) and computerized algorithms (Grzymala-Lubanski, 
Själander, Renlund, Svensson, & Själander, 2013; Dimberg, et al., 2012), these 
algorithms do a poor job of accounting for intra-patient variability (Kangelaris, Bent, 
Nussbaum, Garcia, & Tice, 2009) and do not explicitly optimize the monitoring 
frequency, which would reduce the overall cost of the therapy.  Intra-patient variability 
during maintenance dosing can occur due to a variety of factors such as diet, disease 
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state, and drug interactions. (Ansell, et al., 2008; White, 2010).   In fact, there are 
currently no warfarin dosing algorithms that optimize both the warfarin dose for an 
individual patient as well as the time between INR monitoring visits. 
 
B. Current Warfarin Dosing Methods 
There are three main types of algorithms that are used in clinical practice to 
manage warfarin oral anticoagulant therapy.  These three main types of algorithms 
include dose titration, pharmacogenetic algorithms, and computerized algorithms.  
Warfarin dose titration is exemplified in the dosing protocol dictated by the American 
Society of Hematology, which is the current standard of care (Cushman, Lim, & Zakai, 
2011).  Dose titration algorithms slowly titrate a patient’s warfarin dose until the patient’s 
INR levels are within the therapeutic range, and the method of titrating a patient’s dose 
until the desired effect is achieved is common practice in drug dosing even outside of the 
realm of anticoagulant therapy.  This can be ineffective and slow to respond in the 
presence of intra-patient variability, resulting patient’s INR values being outside of the 
therapeutic range (Wilson, Costantini, & Crowther, 2007).   
Pharmacogenetic algorithms use pharmacogenetic information, specifically, 
variations in the genes CYP2C9 and VKORC1, to select a more accurate initial warfarin 
dose (Carlquist & Anderson, 2011).  While pharmacogenetic algorithms have been 
proven in clinical practice to minimize the effect of inter-patient variability and select a 
more accurate initial warfarin dose (Carlquist & Anderson, 2011), they do nothing to 
account for intra-patient variability due to external factors, which is unhelpful during a 
patient’s maintenance dosing period, and also are yet to gain wide acceptance among 
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physicians.  The required pharmacogenetic testing to determine a patient’s genetic 
variations are also costly and not part of standard clinical practice. 
Computerized algorithms, exemplified by AuriculA (a Swedish national quality 
registry of patients treated with warfarin), use key patient characteristics, and information 
about the warfarin treatment and complications to make dose suggestions (Dimberg, et 
al., 2012).  These algorithms operate according to 720 rules and patient history to make 
dose suggestions (Grzymala-Lubanski, Själander, Renlund, Svensson, & Själander, 
2013).  While these algorithms have been successful in clinical practice, they require 
massive databases of patient information, and also, in the presence of high intra-patient 
variability, still require manual (physician initiated) dose changes.  Another issue with all 
of the algorithms in clinical practice are that there are no dosing algorithms that optimize 
INR measurement and dose change frequency. 
 
C. Objective 
The objective of this study was to develop a new method for dosing warfarin 
based on the control technique of Reinforcement Learning (RL) that will adapt to each 
patient based on feedback from the patient, and will also optimize the time between INR 
measurements.  This new algorithm will help minimize the effect of intra-patient 
variability and reduce the number of INR measurements that are necessary.  Because the 
current standard of care does a poor job of accounting for intra-patient variability and 
does nothing to optimize the time between INR measurements, the ultimate goal of this 
work is for the new warfarin RL algorithm to increase patient’s time in the therapeutic 
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range (TTR) and reduce the overall cost of therapy by optimizing the INR monitoring 
























II. INSTRUMENTATION AND EQUIPMENT 
 
 
 The equipment that was used for the creation of the warfarin RL algorithm was a 
Lenovo ThinkPad Edge laptop with model number 0301-DBU.  The laptop was 
manufactured by Lenovo (Singapore) Pte. Ltd., and it was made in China.  All coding, 
calculations, and graphs were done using MATLAB 7.12.0 R2011a software created by 





















A. Reinforcement Learning Overview 
 Reinforcement Learning (RL) is a control method used to control a system based 
on experience. Elements of Reinforcement Learning include: Environment, which is the 
system that is being affected, State, which is a measurement of the environment, Action, 
which is the control input into the system, Agent, which is the governing body that takes 
the action, and Reward, which identifies how well the agent is performing. This method 
utilizes the Markov Decision Process (MDP) to determine the optimal action to take, 
while in a given state, to achieve a desired state (Sutton & Barto, 1998). The rules 
governing what action to take, while in a given state, to achieve a desired state are known 
as a policy, and the goal of Reinforcement Learning is to determine the optimal policy. 
 One of the most popular RL methods is Q-Learning.  Q- Learning is a type of 
Reinforcement Learning that seeks to maximize the action-value function defined as: 
 
 (         (                    ⏟
 
  (           (                            (1) 
 
In this equation,      is the reward observed after performing action    in state   ,   is the 
learning rate, and   is the discount factor (Sutton & Barto, 1998).  The learning rate 
determines how much the new learning signal will outweigh past learning signals. The 
discount factor determines the significance of future rewards (    will only take into 
account immediate reward, and     will seek a higher cumulative reward). The term 
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   ⏟
 
  (         is an estimate of the optimal future action value.  If the policy is 
represented as a lookup table, this can be a long and arduous process, as the whole state-
action space should preferably be explored during learning, including suboptimal actions.  
Depending on the problem dimensionality, there can be a large number of possible states 
and actions and the learning process may be computationally expensive. 
 Because of the limitations of traditional RL and Q-Learning, a method known as 
Q- Learning with Linear Functional Policy Approximation can help eliminate the need 
for unnecessary exploration, and simplify calculations.  This method translates the state 
into a set of features and actions into a set of symbolic parameters (Irodova & Sloan, 
2005), represented by the equation: 
 
 (        
       
                                                            (2) 
 
In this equation,   …   represent the translated set of states,   
 …  
  represent the 
symbolic parameters, and  (     is the policy.  Using the Q-learning equation (1), the 
following update rule for each parameter (  
 ) can be derived: 
 
  
     
    [      ⏟
  
  (          (    ]
   (    
   
                               (3) 
 
In this equation, (a) represents the most recent action taken, (s) represents the most recent 
state observed,    represents future action, and    represents the future state (Irodova & 
Sloan, 2005). Q-Learning with Linear Functional Policy Approximation eliminates the 
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need to visit many state action pairs during the learning phase, some of which may be 
infeasible or even impossible. 
 
B. Warfarin Q-Learning With Linear Policy Approximation 
Q-Learning with linear functional policy approximation is the control method 
used to determine the optimal dose change,      , and the optimal time between INR 
measurements,      . In this work, the clinical goal of warfarin therapy is to achieve a 
patient INR value of 2.5 represented by          (this value is chosen because it is the 
midpoint of the warfarin therapeutic range of INR = 2.0-3.0).  The control method uses 
the difference between the measured INR value and          , defined by         , as the 
output of the system, where the desired state is for         = 0, defined by               .  
The elements of this method are detailed in FIGURE 1, and the goal of this method is for 




FIGURE 1 - Block Diagram of RL based Warfarin Dosing  
 
 The patient’s body is the environment being affected, and more specifically the 
mechanisms that involve thrombus formation (Hirsh, Fuster, Ansell, & Halperin, 2003; 
Porter, 2010).  In this work, two different patient models are used to represent the 
environment (patient), the control-relevant patient model, and the simulation model. The 
control-relevant patient model is used to design the controllers and is represented as 
follows: 
 





                                                   (4) 
 
In control-relevant patient response model,   represents the gain (INR increase/mg/day 
of warfarin administered), t represents time (in days), and    represents the time constant 
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(time until the administered warfarin dose reaches 32% of its full pharmacodynamic 
(INR) effect).   This model is used for controller design because it can represent the 
properties of the more complex process with sufficient accuracy, while minimizing the 
number of parameters.  The simulation model used for simulation is represented by the 
equation: 
 
   (   (    (       





                                      (5) 
 
In the simulation model,    represents the linear gain (INR increase/mg/day of warfarin 
administered),    represents the nonlinear (quadratic) gain, t represents time (in days), 
and    represents the time constant (time until the administered warfarin dose reaches 
32% of its full pharmacodynamic (INR) effect).  The agent is the body that governs the 
actions that are to be taken.  In this work the agent is represented by the equations: 
 
           (            (                                         (6) 
 
           (            (                                         (7) 
 
The actions, governed by the agent, are       and      , where       is the dose 
change and       is the time between INR measurements.  The state is represented by 





                                                                        (8) 
 
                                                                        (9) 
 
INR is the patient’s current INR value and                 is the         from the 
previous INR measurement.  The reward is a value assigned to the action based on 
whether or not the environment moves closer to the desired state,              . Here, the 




  (         
                                                           (10) 
 
As the INR moves farther away from the target value,              , the reward grows 
smaller, and as the INR moves closer to the target value, the reward grows larger.  The 
maximum reward is R = 1. 
 
C. Reinforcement Learning Warfarin Dosing Algorithm 
The Overall Reinforcement Learning warfarin dosing algorithm is separated into 
2 phases:  
1) Learning phase (off-line) 
2) Dosing phase (on-line) 
The learning phase is the design phase and uses the principles of RL to “learn” the 
optimal parameter values that are implemented to calculate the proper       and       
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during the dosing phase.  The dosing phase uses the optimal parameter values extracted 
from the learning phase to calculate the proper       and       based on         and 
         observed in the individual patient.   
During the learning phase, 9 different controllers are created to optimize the 
warfarin dose for 9 different patient responder types.  These different patient responder 
types range from extremely hypo-responsive (patient has a marginal INR increase 
compared to the dose administered) to extremely hyper-responsive (patient has a 
significant INR increase compared to the dose administered).   To create the different 
controllers, the control-relevant patient response model is used. Nine different K values 
are used to create 9 different controllers, and are listed as follows: 
 
TABLE I 
CONTROL REVELANT K VALUES 
 
These values are listed in order of increasing patient responsiveness ranging from 
extremely hypo-responsive (K = 0.1) to extremely hyper-responsive (K = 0.9).  Three 
hundred learning episodes, each 120 days in length, are performed for each value of K.  
Before the first learning episode for each K value, initial values for the learned 













arbitrary as the optimal parameter values will be determined over the course of the 
learning episodes.  RL parameters   and  , which are the discount factor and the learning 
rate respectively, are also initiated before the first learning episode and have initial values 
of       and       .  The values of the RL parameters are determined heuristically to 
help reduce simulation time.  Once the parameter values and RL variables are initiated, 
the first learning episode begins. 
Step 1: The algorithm calculates the Q values for all of the possible       values 
(-5mg/day, -4.9mg/day, -4.8mg/day…+4.8mg/day, +4.9mg/day, +5mg/day), and the 
calculations are made using the equation:  
 
         
( (     (         (         (          
                       (11) 
 
The       that yields the highest        value is selected as the optimal dose change. 
The same thing is done for      , the algorithm calculates the Q values for all possible 
      values (1-6 weeks) using the equation: 
 
         
( (     (           (          (       
                      (12) 
 
 The       that yields the highest         is then selected, and no INR measurements 
are made until the selected number of weeks has passed.  Step 2: The new       and 
      are simulated using the control-relevant patient model, with the addition of 
random noise to compensate for external factors. A reward is then determined based on 
the difference between the most recent INR measurement and the target INR as governed 
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by equation (10).  Step 3: The reward is then used to calculate value functions for both 
      and       using the equations: 
 
           (    ⏟
        
      (                    )                       (13) 
 
           (    ⏟
        
      (                    )                      (14) 
 
In these equations,         (                     and 
      (                     are estimates of optimal future values.  Step 4: The 
parameters   , a, c, f, h, and    are then updated based on the value functions following 
the form listed in equation (3). The update equations are described as follows: 
 
     (               (
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   = 0 remains constant. 
Steps 1-4 are repeated until the length of the simulation meets or exceeds 120 days 
(        ), and once this occurs, the learning episode is finished.  The learning rate is 
then reduced using the equation:  
    (                                                              (20) 
Once the learning rate is updated, the learning episode is completed, and a new learning 
episode begins.  Each new learning episode exploits the previously learned parameter 
values   , a, c, f, h, and   , so that they are continuously updated during each learning 
episode.  When all 300 learning episodes are completed, the learned optimal parameter 
values   , a, c, f, h, and    are extracted. 
The Dosing Phase can begin once the learning phase is complete.  During the 
initiation of dosing, an initial dose of 5mg/day of warfarin is given to the patient.  
Patient’s INR measurements are taken on a weekly basis (days 7, 14, and 21), and after 
the measurement is taken, a new dose is determined by the algorithm and administered to 
the patient until it is time for the next INR measurement.  To adjust the dose, a control-
relevant K value is estimated based on the most recent dose using the equation: 
 
    
   
    
                                                            (21) 
 
The K value from table 1 that is closest to the calculated     value is then selected as the 
control-relevant K value. The value of 1.5 is used in the first equation because that is the 
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difference between the patient’s initial INR value (1) and the target INR value.  Once the 
control-relevant K value is determined, the parameters associated with that control-
relevant K value,          and          are used to determine the new dose: 
 
                                                                (22) 
 
In this equation,              is the most recent dose given to the patient before the INR 
measurement.  The calculated new dose is then given to the patient until the next INR 
measurement, and this process is repeated on day 7, 14, and 21 (initiation phase).  After 
day 21 (maintenance phase),       is determined by the equation (7).  After day 21, INR 
is only measured when the algorithm suggests.  For maintenance dosing, the patient’s 
INR is measured when       suggests, the control-relevant K value is estimated, and the 
new Dose and       are calculated. 
To prove the efficacy of the new RL warfarin algorithm, three simulations were 
performed on each of 100 artificial patients (with varying warfarin responses), and each 
patient was simulated for 180 days of therapy.  The first simulation was performed as an 
ideal case scenario (random noise with CV = 0%) for verification of the RL warfarin 
algorithm in the presence of no intra-patient variability. It is, however, impossible to 
eliminate intra-patient variability in a real world scenario, so two more simulations were 
performed to compare the industry standard of care to the RL warfarin algorithm.  The 
second simulation was performed following the guidelines for dosing and INR 
measurements stipulated in the current standard of care, and a CV = 25% was used to 
simulate extreme intra-patient variability.  The third simulation was performed following 
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guidelines stipulated by the RL warfarin algorithm, and this simulation also used a CV = 
25% to simulate extreme intra-patient variability.  Simulations two and three were then 
used to compare the industry standard of care to the RL warfarin algorithm using %TTR 






















VI. RESULTS AND DISCUSSION 
 
 All simulations, calculations, and graphs were performed and made using 
MATLAB software.  Before simulation using the RL could take place, the learning phase 
to determine the optimal parameter values associated with each control-relevant K value 




K    a c f h    
0.1 0 -3.00367 0.607573 0.413057 -3.79183 4.407258 
0.2 0 -2.25922 0.562711 0.737318 -3.35005 4.774702 
0.3 0 -0.82387 0.813361 0.573093 -3.47947 4.598232 
0.4 0 -0.4069 0.737377 0.057894 -4.13071 3.924247 
0.5 0 -0.58846 0.699238 0.835709 -3.10336 4.885482 
0.6 0 -0.26811 0.564213 0.123133 -4.27049 3.988894 
0.7 0 -0.25454 0.571812 0.274075 -4.01829 4.225859 
0.8 0 -0.1582 0.503708 0.154036 -4.37039 3.982359 
0.9 0 -0.19254 0.446211 0.232318 -4.13157 4.19317 
 
The control relevant K values are listed in the first column of TABLE 2, and the 
remaining columns list the parameter values associated with the control relevant K value 
in the same row.  The values for parameter “a” trended towards 0 as the control relevant 
K value increased.   When the values for parameter “a” were looked at in the context of 
equation (6), it indicated that when the patient became more responsive to the warfarin 
dose (control relevant K value increased), the same         values would result in a 
smaller dose change.  This means that if a patient was determined to have a high control 
relevant K value, a smaller dose change is necessary to achieve the desired effect.  
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The results for parameter value “c” varied, which indicated that          had a 
varying effect depending on the responder type.  The parameter values for “  ”, when 
taken in context of equation (7), were determined to be the optimal times between INR 
measurements when the         and          values were both 0, which would mean the 
patient had reached the target values for         and         .  The parameter values for 
both “f” and “h” varied, which indicated that the values for         and          had 
varying effects depending on the control relevant K value, respectively, when taken in the 
context of equation (7). 
 The first simulation was performed using only the RL algorithm in the presence 
of no intra-patient variability (CV = 0%) and the results were as follows: 
 
TABLE 3 
SIMULATION 1 RESULTS 
Simulation 
Dosing 
Algorithm CV %TTR 
%TTR standard 
deviation 
mean # of INR 
Measurements 
1 RL 0% 92.1% 4.2% 7.94/patient 
 
The first simulation, represented in TABLE 3, yielded a mean %TTR = 92.1% over all 
100 artificial patients, with a standard deviation of 4.2%, and had a mean number of INR 
measurements = 7.94 measurements/patient. These results indicated, that in the presence 
of no intra-patient variability, the RL algorithm did an exceptional job of keeping the 
simulated patients’ INR values within the therapeutic range.  The reason the RL 
algorithm was not able to attain a higher %TTR was due to 2 factors.  First, each patient 
started off with an INR value of 1, meaning that there was always a time when the 
patient’s INR values were not in therapeutic range.  Second, the initial dose given to the 
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patient was 5mg/day (the American Society of Hematology recommended starting dose 
(Cushman, Lim, & Zakai, 2011)), which, in the cases of the medium and hyper responder 
types (see FIGURES 3 and 4), can cause an overshoot of the therapeutic range due to an 
incorrect initial dose and not due to controller action.  FIGURES 2, 3, and 4 are sample 
plots of the results that were attained from single patient types (hypo, medium, and hyper 
responders).  A comparison to the current standard of care was still necessary to prove 
that the RL algorithm was viable. 
 
FIGURE 2 - Sample plot of a single patient - Hypo-Responder. The top plot is the 
patient’s INR response, where the blue line is INR and the red lines indicate therapeutic 





FIGURE 3 - Sample plot of a single patient - Medium-Responder. The top plot is the 
patient’s INR response, where the blue line is INR and the red lines indicate therapeutic 





FIGURE 4 - Sample plot of a single patient - Hyper-Responder. The top plot is the 
patient’s INR response, where the blue line is INR and the red lines indicate therapeutic 
range.  The bottom plot is the dose.  
 
 The second simulation was performed with all 100 artificial patients using the 
American Society of Hematology dosing algorithm (represented as ASH in TABLE 4), 
which is the current standard of care, and the third simulation was performed with all 100 
artificial patients using the warfarin RL algorithm (indicated in TABLE 4 as RL).  
Simulations two and three were both performed in the presence of heavy intra-patient 







SIMULATIONS 2 AND 3 RESULTS 
Simulation 
Dosing 









2 ASH 25% 45.3% 16.4% 12.30/patient 
<.001 3 RL 25% 51.8% 10.8% 8.05/patient 
 
 The second simulation, represented in TABLE 4, yielded a mean %TTR = 45.3% 
over all 100 artificial patients, with a standard deviation of 16.4%, and had a mean 
number of INR measurements = 12.3 measurements/patient. The third simulation, 
represented in TABLE 4, yielded a mean %TTR = 51.8% over all 100 artificial patients, 
with a standard deviation of 10.8%, and had a mean number of INR measurements = 8.05 
measurements/patient.  There was determined to be a statistically significant difference 
(P<.001) between the American Society of Hematology algorithm and the warfarin RL 
algorithm.  Figures 5, 6, and 7 are sample plots of the results that were attained from 




FIGURE 5 - Sample plot of a single patient - Hypo-Responder. The top plot is the 
patient’s INR response using the RL algorithm, where the blue line is INR and the red 







FIGURE 6 - Sample plot of a single patient - Medium-Responder. The top plot is the 
patient’s INR response using the RL algorithm, where the blue line is INR and the red 






FIGURE 7 - Sample plot of a single patient - Hyper-Responder. The top plot is the 
patient’s INR response using the RL algorithm, where the blue line is INR and the red 





The results listed in TABLE 4 indicated that the warfarin RL algorithm not only 
did a better job at keeping the patient’s INR in therapeutic range, but also reduced the 
number of INR measurements that were required per patient.  When translated into a real 
world scenario, the data from TABLE 4 indicated that the warfarin RL algorithm would 
result in greater patient safety and therapeutic efficacy by keeping the patient’s INR 
values in therapeutic range for a greater amount of time than the current standard of care.  
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The warfarin RL algorithm was also able to reduce the mean number of INR 
measurements that were necessary over all 100 artificial patients, which indicated that the 
overall cost of the warfarin therapy when using the warfarin RL algorithm would be less 
than the cost of warfarin therapy when using current standard of care. 
 The %TTR values listed in TABLE 4 correspond closely with %TTR values that 
are typically seen in clinical practice (Wilson, Costantini, & Crowther, 2007).  The 
warfarin RL algorithm performed better than the current standard of care (ASH 
algorithm) at keeping patient’s INR values in the therapeutic range due to its ability to 
switch between controllers to match each patient’s response instead of slowly titrating the 
dose until the desired effect is achieved.  When a patient is matched to their respective 
control relevant K value, the algorithm is able to make smaller or larger dose changes to 
match the possible patient response, whereas the ASH algorithm uses titration to achieve 
the desired INR value.  This means that the warfarin RL algorithm is able to respond 
faster and better when a patient’s response to warfarin dose changes, which can occur due 
to intra-patient variability factors (diet, drug interactions, and disease state), than titration 
based algorithms. 
 The mean number of INR measurements that were necessary, listed in TABLE 4, 
are another important factor to consider when comparing the warfarin RL algorithm with 
the current standard of care.  As previously stated, utilizing the warfarin RL algorithm 
resulted in a fewer number if INR measurements that were necessary when compared to 
the current standard of care, and that would result in a reduction of the overall cost of the 
therapy.  The rising cost of healthcare and the uncertain changes that are occurring in the 
U.S. healthcare market are important considerations when evaluating this metric.  If a 
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patient could receive superior healthcare at a lower cost, the patient would be, overall, 
more satisfied.  Also, the cost of warfarin therapy is more than just monetary, and patient 
convenience is an important factor to consider.  If fewer INR measurements were 
necessary over the course of warfarin therapy, this would greatly increase patient 
convenience and quality of life. 
Drug dosing as a whole, even outside of the realm of warfarin and anticoagulants, 
could greatly benefit from the use of engineering methods like the one presented in this 
study.  For most drugs, outdated dosing methodologies are used to slowly titrate the dose 
until a desirable effect is achieved.  These methodologies can be inefficient, and can even 
have the potential to be dangerous if the proper dose is not determined fast enough or the 
methodology used is slow to respond to inter and intra patient variability.  There is a need 
for the development of new dosing methodologies that utilize engineering methods to 
improve patient safety, and reduce the cost of different types of therapy by more 
“intelligently” dosing patients.   
These methods could be applied to drugs like Plavix, which is an antiplatelet 
agent, and also other unrelated drugs such as erythropoiesis stimulating agents, which are 
used to stimulate red blood cell production in patients with End Stage Renal Disease.  In 
fact, there is evidence in the literature which suggests that control systems engineering 
methodologies have been effective in real life clinical settings (Gaweda, Jacobs, Arnoff, 
& Brier, 2008).  If the medical community were to develop and adopt “smarter” dosing 
protocols based on control systems engineering techniques, patient’s receiving a variety 






 Based on the data from the simulations that were performed, the patient 
population as a whole could greatly benefit from using the RL warfarin algorithm as an 
alternative to the current standard of care.  Using the RL warfarin algorithm could help 
keep patient’s INR in therapeutic range in the presence of heavy intra-patient variability 
while also greatly reduce the cost of the therapy by optimizing the number of INR 
measurements that are required.  The RL Warfarin Algorithm offers distinct advantages 
compared to the industry standard dosing methods, and while there are other 
computational and evidence based algorithms in practice, no other algorithm optimizes 
monitoring frequency.  Next, a human study of the RL warfarin algorithm should be 
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